Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.65 +0.52 (+2.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,897,077
Open 25.18
Bid (Size) 25.56 (1)
Ask (Size) 25.61 (29)
Prev. Close 25.13
Today's Range 25.10 - 25.75
52wk Range 24.48 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 6.55%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS. 
Via Benzinga
Topics Government
Exposures Political
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
Via Investor's Business Daily

Performance

YTD
-13.72%
-13.72%
1 Month
-11.12%
-11.12%
3 Month
-11.25%
-11.25%
6 Month
-11.18%
-11.18%
1 Year
-15.90%
-15.90%

More News

Read More
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Via The Motley Fool
Is Biotech’s Bull Run Over? Examining Election Impacts
Via MarketBeat
Topics ETFs Government
Exposures Political
Pfizer Unusual Options Activity For November 20
Via Benzinga
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Via The Motley Fool
Stock Of The Day: Is Pfizer Set Up To Rally?
Via Benzinga
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Via The Motley Fool
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
Via Benzinga
Pfizer Announces New Chief Scientific Officer and President, Research & Development
From Pfizer Inc.
Via Business Wire
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
Unpacking the Latest Options Trading Trends in Pfizer
Via Benzinga
Key Takeaways From Pfizer Analyst Ratings
Via Benzinga
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Via Benzinga
2 High-Yield Dividend Stocks I Can't Stop Buying
Via The Motley Fool
Not-So-Big Pharma
Via Talk Markets
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Via MarketBeat
Friday's Top 5 Trending Stocks: What's The Scoop On Palantir, Bloom Energy, Pfizer?
Via Benzinga
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
Via Investor's Business Daily
Topics Government
Exposures Political
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
Via Benzinga
Topics Government
Exposures Political
This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
US Stocks Likely To Open In Red After Jerome Powell Says No Need To Be 'In A Hurry' On Rate Cuts: Tesla, TSMC And Domino's In Focus
Via Benzinga
Topics Economy
Exposures Economy Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.